CA2657041C - Method for producing insulin analogs having a dibasic b chain terminus - Google Patents

Method for producing insulin analogs having a dibasic b chain terminus Download PDF

Info

Publication number
CA2657041C
CA2657041C CA2657041A CA2657041A CA2657041C CA 2657041 C CA2657041 C CA 2657041C CA 2657041 A CA2657041 A CA 2657041A CA 2657041 A CA2657041 A CA 2657041A CA 2657041 C CA2657041 C CA 2657041C
Authority
CA
Canada
Prior art keywords
insulin
amino acid
arg
chain
naturally occurring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2657041A
Other languages
English (en)
French (fr)
Other versions
CA2657041A1 (en
Inventor
Paul Habermann
Frank Zocher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CA2657041A1 publication Critical patent/CA2657041A1/en
Application granted granted Critical
Publication of CA2657041C publication Critical patent/CA2657041C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2657041A 2006-07-11 2007-07-05 Method for producing insulin analogs having a dibasic b chain terminus Expired - Fee Related CA2657041C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006031955.9 2006-07-11
DE102006031955A DE102006031955A1 (de) 2006-07-11 2006-07-11 Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
PCT/EP2007/005933 WO2008006497A1 (de) 2006-07-11 2007-07-05 Verfahren zur herstellung von insulinanaloga mit dibasischem b-kettenende

Publications (2)

Publication Number Publication Date
CA2657041A1 CA2657041A1 (en) 2008-01-17
CA2657041C true CA2657041C (en) 2016-04-26

Family

ID=38468893

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2657041A Expired - Fee Related CA2657041C (en) 2006-07-11 2007-07-05 Method for producing insulin analogs having a dibasic b chain terminus

Country Status (19)

Country Link
US (1) US8410048B2 (enExample)
EP (1) EP2041170B1 (enExample)
JP (1) JP5331685B2 (enExample)
KR (1) KR101439110B1 (enExample)
CN (1) CN101490082B (enExample)
AR (1) AR061865A1 (enExample)
AU (1) AU2007272057B2 (enExample)
BR (1) BRPI0714297A2 (enExample)
CA (1) CA2657041C (enExample)
DE (1) DE102006031955A1 (enExample)
DK (1) DK2041170T3 (enExample)
ES (1) ES2423684T3 (enExample)
IL (1) IL196360A (enExample)
MX (1) MX2009000275A (enExample)
MY (1) MY148984A (enExample)
NO (1) NO20090663L (enExample)
PT (1) PT2041170E (enExample)
TW (1) TWI440717B (enExample)
WO (1) WO2008006497A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046113A1 (de) * 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
CA2705821A1 (en) 2007-11-16 2009-05-22 Novo Nordisk A/S Pharmaceutical compositions containing insulin and an insulinotropic peptide
MY161892A (en) * 2008-02-19 2017-05-15 Biocon Ltd A method of obtaining a purified, biologically active heterologous protein
WO2012015692A2 (en) * 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
WO2013015697A1 (en) 2011-07-28 2013-01-31 Mabion S.A. A recombinant protein, a polynucleotide encoding it as well as a method of obtaining insulin or its an analogue
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
PL233560B1 (pl) 2014-12-05 2019-10-31 Mabion Spolka Akcyjna Sposób otrzymywania insuliny lub analogu insuliny z prekursora rekombinowanego białka

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55138393A (en) * 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3636903A1 (de) 1985-12-21 1987-07-02 Hoechst Ag Fusionsproteine mit eukaryotischem ballastanteil
GB8618152D0 (en) * 1986-07-25 1986-09-03 Renishaw Plc Co-ordinate measuring
EP0294851A3 (de) * 1987-06-12 1990-05-09 Berlin-Chemie Ag Verfahren zur Herstellung von Humaninsulin und seinen Derivaten
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE3844211A1 (de) 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5227293A (en) 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
DE4405179A1 (de) 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AR025646A1 (es) * 2000-09-13 2002-12-04 Beta Lab Sa Cepa de levaduras metilotroficas recombinantes productoras de un precursor de insulina, construcciones de adn y metodo para obtener la cepa.
DE10108211A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
DE10108100A1 (de) 2001-02-20 2002-08-29 Aventis Pharma Gmbh Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
IL161358A0 (en) * 2001-11-19 2004-09-27 Novo Nordisk As Process for preparing insulin compounds
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
EP1778839B1 (en) 2004-08-13 2008-07-09 Roche Diagniostics GMBH C-terminal modification of polypeptides
DE102004058306A1 (de) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
DE102005046113A1 (de) * 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen

Also Published As

Publication number Publication date
CN101490082A (zh) 2009-07-22
ES2423684T3 (es) 2013-09-23
AU2007272057B2 (en) 2012-06-14
AR061865A1 (es) 2008-09-24
WO2008006497A1 (de) 2008-01-17
PT2041170E (pt) 2013-07-18
DE102006031955A1 (de) 2008-01-17
NO20090663L (no) 2009-02-11
BRPI0714297A2 (pt) 2013-02-26
TWI440717B (zh) 2014-06-11
IL196360A (en) 2015-08-31
EP2041170B1 (de) 2013-05-01
US20090192073A1 (en) 2009-07-30
JP2009542235A (ja) 2009-12-03
EP2041170A1 (de) 2009-04-01
JP5331685B2 (ja) 2013-10-30
KR101439110B1 (ko) 2014-09-12
MY148984A (en) 2013-06-28
MX2009000275A (es) 2009-01-26
HK1130815A1 (en) 2010-01-08
DK2041170T3 (da) 2013-08-05
CA2657041A1 (en) 2008-01-17
AU2007272057A1 (en) 2008-01-17
IL196360A0 (en) 2011-08-01
TW200817511A (en) 2008-04-16
CN101490082B (zh) 2013-08-14
KR20090038868A (ko) 2009-04-21
US8410048B2 (en) 2013-04-02

Similar Documents

Publication Publication Date Title
CA2657041C (en) Method for producing insulin analogs having a dibasic b chain terminus
CA2438886A1 (en) Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture
PL180818B1 (pl) Sposób wytwarzania insuliny ludzkiej, oraz polipeptyd hybrydowy
KR100659671B1 (ko) 신규한 융합단백질로부터 재조합 인슐린을 제조하는 방법
CN113614113B (zh) 含有荧光蛋白片段的融合蛋白及其用途
CN101605889A (zh) 含有高表达分泌胰岛素前体的融合蛋白、编码该融合蛋白的dna和胰岛素的制备方法
HK1130815B (en) Method for producing insulin analogs having a dibasic b chain terminus

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180705